Kidney transplant drug approved
- FDA on Cladribine. // Momentum (19403410);Summer2011, Vol. 4 Issue 3, p23
The article reports on the ruling by the U.S. Federal Drug Administration (FDA) declining marketing approval for oral Cladribine intended for relapsing forms of multiple sclerosis (MS).
- Multipl Sklerozda FDA OnaylÄ± Ä°lk Oral Ajan: Fingolimod. AKMAN-DEM#305;R, Gülşen // Archives of Neuropsychiatry / Noropsikiatri Arsivi;Dec2011 Supplement, Vol. 48, p64
Disease-modifying drugs (DMDs) are being used in multiple sclerosis (MS) for the last 20 years. Until recently, only interferon beta and glatiramer acetate preparations were available, which are administered by repetitive injections. In the last quarter of 2010, the USA Food and Drug...
- FDA approves first oral MS disease-modifier. // Momentum (19403410);Winter2010/2011, Vol. 4 Issue 1, p21
The article announces the decision of the U.S. Food and Drug Administration (FDA) on Septembeer 21, 2010 to approve fingolimod capsules (Gilenya) as treatment of multiple sclerosis in relapsing forms.
- Immunosuppressants. // Reactions Weekly;9/3/2011, Issue 1367, p23
The article describes the clinical cases of four renal transplant patients who developed malignancies associated with their disused arteriovenous fistulae (AVF) while under immunosuppressant therapies.
- New drugs. // Drug Topics;6/1/98, Vol. 142 Issue 11, p83
Reports that in 1998 the United States Food and Drug Administration approved Novartis Pharmaceutical Corporation's drug Simulect, an immunosuppressant, for the prevention of acute rejection episodes in renal-transplant recipients. How this drug works; Recommended dosage for this drug;...
- Diarrhea in a post-renal transplant child: Questions. Wiley, Jasmine; Shivaram, Pushpa; Resnick, Jeffrey; Fish, Daryl; Park, Roger; Haws, Robert // Pediatric Nephrology;Apr2015, Vol. 30 Issue 4, p589
The article presents a case study of a 14-year-old boy with the status of post-living relative renal transplant is presented. His past medical history includes bilateral Wilms tumor with multiple recurrences, subsequent bilateral nephrectomies and living relative renal transplant. On examining...
- Management and prevention of post-transplant malignancies in kidney transplant recipients. Stallone, Giovanni; Infante, Barbara; Grandaliano, Giuseppe // Clinical Kidney Journal;Oct2015, Vol. 8 Issue 5, p637
The central issue in organ transplantation remains suppression of allograft rejection. Thus, the development of immunosuppressive drugs has been the key to successful allograft function. The increased immunosuppressive efficiency obtained in the last two decades in kidney transplantation...
- Sirolimus-induced pneumonitis. Singh, U.; Gupta, A.; Jasuja, S. // Journal of Conservative Dentistry;Jan/Feb2009, Vol. 12 Issue 1, p80
The article presents a case study of a 15 year-old girl with reflux nephropathy ESKD who underwent a related renal transplant. It states that the patient was given initial immunosuppresant agents such as cyclosporine, azathioprine, and prednisolone. It notes that after four years of medication,...
- Lymphatic disorders after renal transplantation: new insights for an old complication. Ranghino, Andrea; Segoloni, Giuseppe Paolo; Lasaponara, Fedele; Biancone, Luigi // Clinical Kidney Journal;Oct2015, Vol. 8 Issue 5, p615
In renal transplanted patients, lymphoceles and lymphorrhea are well-known lymphatic complications. Surgical damage of the lymphatics of the graft during the procurement and of the lymphatic around the iliac vessels of the recipients has been associated with development of lymphatic...